Q1 2025 Precipio Inc Earnings Call Transcript
Key Points
- Precipio Inc (PRPO) reported a 43% year-over-year increase in Q1 2025 revenues, reaching $4.9 million, indicating sustained demand and growth in pathology services.
- Adjusted EBITDA improved by 92%, with a loss of $108,000 compared to a $1.4 million loss in Q1 of the previous year, showcasing enhanced operational efficiency.
- Pathology division test volume increased by 46% and revenue grew by 53% year-over-year, with 11 new physicians utilizing their services, reflecting strong market trust.
- Gross margins for the Pathology division increased from 24% to 42% year-over-year, driven by operational efficiency and scale.
- Precipio Inc (PRPO) received MolDx approval for next-generation sequencing (NGS) testing, which is expected to increase revenue and cash flow by approximately $0.25 million per quarter.
- Q1 2025 revenues decreased by 9.5% from Q4 2024, attributed to typical seasonal patterns in the healthcare industry.
- The FDA ruling on laboratory developed tests (LDTs) caused delays in customer adoption of Precipio Inc (PRPO)'s technology, impacting growth.
- Product division revenues were flat from Q4 2024 to Q1 2025, with customer validation timelines largely out of the company's control.
- The company experienced a temporary disruption in billing and collections due to a cyber-attack on Change Healthcare in early 2024.
- Precipio Inc (PRPO) is still pursuing the remaining $1 million from the CARES Act employee retention credit, indicating potential delays in receiving these funds.
Welcome to the Precipio first-quarter 2025 shareholder update conference call. (Operator Instructions) Please note that the conference is being recorded.
Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these statements are based upon our current expectations, forecasts and assumptions and are subject to significant risks and uncertainties.
These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue or the negative of these terms or other words or terms of similar meaning.
Risks and uncertainties that could cause our actual results to differ materially from those set forth in any forward-looking statements include, but are not limited to, the matters listed under risk factors in our annual report on Form 10-K for the year ended December 31, 2024, which is on file with the Securities and Exchange Commission, as well as other risks detailed in our subsequent filings
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
